Neoplasms

Mouth and Tooth Diseases

All Conditions

Rare Diseases

Mouth Neoplasms

Head and Neck Neoplasms

Mouth Diseases

Stomatognathic Diseases

Oral Cancer

Lip and Oral Cavity Cancer

Antineoplastic Agents

All Drugs and Chemicals

Everolimus

Exemestane

Letrozole

Nilotinib

Sunitinib

Imatinib Mesylate

Deferasirox

Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox

Bugnon Olivier, Professor

Lüthi François, Dr

Schneider Marie-Paule, PhD

Chevaux Bernard, Dr

Troxler Stéphanie, PhD Student

Leila Achtari, MD

The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.

80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).

Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

MEMS data, completed by informations given in motivational interviewing

Evaluating the implementation of the program in pharmacies

By MEMS data and motivational interviewing informations

To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.

Centre Hospitalier Universitaire Vaudois

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Study title	NCT ID	Conditions	Eligibility	Organization
Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment	NCT01370980	Cancer	18 Years -	Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment	NCT01370980	Cancer	18 Years -	Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment	NCT01370980	Cancer	18 Years -	Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Spots Global Cancer Trial Database for exemestan

Every month we try and update this database with for exemestan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for exemestan

Every month we try and update this database with for exemestan cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for exemestan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.